CKAP4: A Potential Drug Target with Unique Characteristics (G10970)

Target Name: CKAP4

NCBI ID: G10970

CKAP4

CKAP4: A Potential Drug Target with Unique Characteristics

CKAP4, also known as SLC30A8, is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and liver. It is a member of the superfamily of transmembrane protein serpins, which are a type of transmembrane protein that plays a structural and regulatory role in various physiological processes.

One of the unique features of CKAP4 is its unique structure. It is a type of transmembrane protein that has a hinge-like shape, which allows it to span the cell membrane and interact with various signaling molecules. This unique structure gives CKAP4 its unique function in cellular signaling, as it allows it to interact with a variety of signaling molecules, including neurotransmitters, hormones, and other signaling molecules.

CKAP4 has also been shown to play a role in various physiological processes, including cell signaling, neurotransmission, and inflammation. For example, studies have shown that CKAP4 is involved in the regulation of neurotransmitter release from neurons, and that it plays a role in the development of neurodegenerative diseases such as Alzheimer's disease.

In addition to its role in cellular signaling, CKAP4 has also been shown to be a potential drug target. Its unique structure and various functions make it an attractive target for drug development, as it is possible to target specific regions of the protein and disrupt its function without affecting the overall structure and function of the cell.

One of the main advantages of CKAP4 as a drug target is its accessibility. Its hinge-like shape allows it to be easily targeted by small molecules, which can be used to disrupt its function. This accessibility has led to a significant number of studies focused on the development of small molecules that can inhibit the activity of CKAP4.

In addition to its accessibility, CKAP4 has also been shown to be a potent drug target due to its high degree of expression. Studies have shown that CKAP4 is highly expressed in various tissues and that it is a good candidate for drug targeting. This high degree of expression makes it possible to use small molecules to disrupt its function even in the presence of normal cellular activity.

Another advantage of CKAP4 as a drug target is its ability to interact with a variety of signaling pathways. Its unique structure allows it to interact with a variety of signaling molecules, including neurotransmitters, hormones, and other signaling molecules. This interaction with multiple signaling pathways makes it a versatile target for drug development.

In conclusion, CKAP4 is a protein that has unique characteristics that make it an attractive drug target. Its accessibility, high degree of expression, and ability to interact with multiple signaling pathways make it a promising target for drug development. Further research is needed to understand the full potential of CKAP4 as a drug target and to develop safe and effective drugs that can disrupt its function.

Protein Name: Cytoskeleton Associated Protein 4

Functions: Mediates the anchoring of the endoplasmic reticulum to microtubules

The "CKAP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKAP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets